For more than 30 years, researchers have identified and quantified genetic and lifestyle factors for Alzheimer’s Disease (AD) and other dementias. Despite extensive research, the fundamental mechanisms behind these neurodegenerative diseases are still not fully understood, and effective management of AD is taking longer than expected.
BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology – Biotech Investments
EQS-News: BRAIN Biotech AG / Key word(s): Contract BRAIN Biotech AG and Akribion Therapeutics GmbH sign exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology 31.10.2024